Skip to content
DraconiticResearch
Search Sources API
203,234 studies31 sourcesUpdated 43 min ago
Peer-reviewedCC BY 4.0Exploration

Soluble Nanomedicine Against Soluble Neurosensitizers to Effectively Relieve Osteoarthritis Pain and Joint Damage

  • Junyan Liu1,2
  • Feixiang Ding3
  • Jiayi Li4
  • Min Liu3
  • Lingyu Su3
  • Zixi Wang3
  • Congying Pi3
  • Shilong Jiang5
  • Zhaokui Zeng3
  • Changjun Li6,7
  • Chao Zeng2,6,8,9
  • Guanghua Lei2,6,8,9
1 more authors
  • Kelong Ai3
9 affiliations
  1. 1Department of Orthopaedics The Third Xiangya Hospital Central South University Changsha China
  2. 2Department of Orthopaedics Xiangya Hospital Central South University Changsha China
  3. 3Xiangya School of Pharmaceutical Sciences Central South University Changsha China
  4. 4Department of Pharmacology and Chemical Biology College of Basic Medical Sciences Shanghai Jiao Tong University School of Medicine Shanghai China
  5. 5Department of Pharmacy Xiangya Hospital Central South University Changsha China
  6. 6Key Laboratory of Aging‐Related Bone and Joint Diseases Prevention and Treatment Ministry of Education Xiangya Hospital Central South University Changsha China
  7. 7Department of Endocrinology Endocrinology Research Center Xiangya Hospital of Central South University Changsha China
  8. 8Hunan Key Laboratory of Joint Degeneration and Injury Changsha China
  9. 9National Clinical Research Center for Geriatric Disorders Xiangya Hospital Central South University Changsha China
Read full textPDFDOICite

Abstract

Targeting soluble neurosensitizers in the osteoarthritis (OA) joint cavity is a key strategy for alleviating OA pain. Soluble neurosensitizers are ubiquitous in the joint cavity and cause uncontrollable growth and sensitization of nociceptor axons therein. However, eliminating these soluble nerve growth factors (NGFs) remains a considerable challenge due to the diversity of neurosensitizers and the complexity of OA pathology. This study introduces an innovative soluble nanodrug (LAC)‐based strategy to eliminate three key neurosensitizers (H+, NGF, and netrin‐1) to simultaneously relieve OA‐associated pain and joint damage. In two animal model experiments, LAC significantly reduced pain and alleviated OA progression by reducing synovial inflammation and inhibiting cartilage and subchondral bone damage. This strategy of using soluble nanomedicine to counter soluble neurosensitizers not only provides inspiration for eliminating pain, but also sheds light on possible solutions for advancing OA treatment strategies.

Related

  1. The Soluble Secretome and Extracellular Vesicles of Synovial Fluid Cells Closely Resemble Synovial Membrane Fibroblasts over Articular Chondrocytes in Donor-Matched Isolates from Osteoarthritis Patients
    Enrico Ragni, Paola De Luca, Michela Maria Taiana +3
    Journal of Clinical MedicinePeer-reviewedCC BY 4.0General medicineCrossref
  2. Bioactive isoprenylflavonoids contribute to the dual protective effects of Xianling Gubao against sarcopenia and osteoarthritis in SAMP8 mice
    Wenyao Yang, Bimin Gao, Jiming Li +11
    Journal of Orthopaedic TranslationPeer-reviewedCC BY-NC-ND 4.0Full textGeneral medicinePMC
  3. Guideline-Concordant Answer Quality of Five Large Language Models on Indication Criteria for Total Hip Arthroplasty in Hip Osteoarthritis: A Single-Run Benchmark Against the 2021 German S3 Guideline (EKIT-Hip)
    Obada Alalman, Max J. Scheyerer, Wajjahat Syed +7
    Journal of Clinical MedicinePeer-reviewedCC BY 4.0Full textEpidemiology & public healthCrossrefEurope PMC
  4. Visceral metastatic angiosarcoma treated effectively with oral cyclophosphamide combined with propranolol
    Justine Daguzé, Mélanie Saint-Jean, Lucie Peuvrel +4
    JAAD Case reportsPeer-reviewedCC BY-NC-ND 4.0Full text29 citedOncologyHAL
  5. Clinician recommendations for effectively incorporating digital information into person-centered contraceptive counseling with adolescents
    Cambray Smith PhD, Elizabeth Pleasants DrPH, MPH, Sarah Rebbeor MS +3
    Women's HealthPeer-reviewedCC BYFull textEpidemiology & public healthDOAJ

Cite

BibTeXRIS
BibTeX
@article{liu2026soluble,
  title = {{Soluble Nanomedicine Against Soluble Neurosensitizers to Effectively Relieve Osteoarthritis Pain and Joint Damage}},
  author = {Junyan Liu and Feixiang Ding and Jiayi Li and Min Liu and Lingyu Su and Zixi Wang and Congying Pi and Shilong Jiang and Zhaokui Zeng and Changjun Li and Chao Zeng and Guanghua Lei and Kelong Ai},
  journal = {Exploration},
  year = {2026},
  month = oct,
  doi = {10.1002/exp2.70233},
  url = {https://doi.org/10.1002/exp2.70233},
  note = {CC BY 4.0},
}
RIS
TY  - JOUR
TI  - Soluble Nanomedicine Against Soluble Neurosensitizers to Effectively Relieve Osteoarthritis Pain and Joint Damage
AU  - Junyan Liu
AU  - Feixiang Ding
AU  - Jiayi Li
AU  - Min Liu
AU  - Lingyu Su
AU  - Zixi Wang
AU  - Congying Pi
AU  - Shilong Jiang
AU  - Zhaokui Zeng
AU  - Changjun Li
AU  - Chao Zeng
AU  - Guanghua Lei
AU  - Kelong Ai
PY  - 2026
DA  - 2026/10/08
JO  - Exploration
DO  - 10.1002/exp2.70233
UR  - https://doi.org/10.1002/exp2.70233
AB  - Targeting soluble neurosensitizers in the osteoarthritis (OA) joint cavity is a key strategy for alleviating OA pain. Soluble neurosensitizers are ubiquitous in the joint cavity and cause uncontrollable growth and sensitization of nociceptor axons therein. However, eliminating these soluble nerve growth factors (NGFs) remains a considerable challenge due to the diversity of neurosensitizers and the complexity of OA pathology. This study introduces an innovative soluble nanodrug (LAC)‐based strategy to eliminate three key neurosensitizers (H+, NGF, and netrin‐1) to simultaneously relieve OA‐associated pain and joint damage. In two animal model experiments, LAC significantly reduced pain and alleviated OA progression by reducing synovial inflammation and inhibiting cartilage and subchondral bone damage. This strategy of using soluble nanomedicine to counter soluble neurosensitizers not only provides inspiration for eliminating pain, but also sheds light on possible solutions for advancing OA treatment strategies.
SN  - 2766-8509
SN  - 2766-2098
ER  -